EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Intraprostatic steroid hormones and endocrine disruptors in prostate cancer

Jana Vitku iD, Tereza Skodova, Anezka Varausova, Lukas Gadus, Michal Horenitzky, Marie Novakova, Martin Hill, Michaela Svojtkova, Lucie Kolatorova, Adela Lukaskova, Jiri Heracek

Endocrine-Related Cancer · 01.07.2026 · 33 (7)

DOI: 10.1530/erc-26-0153 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrine-Related Cancer, online erschienen am 11.06.2026. Verfasst von Jana Vitku und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Steroids and Proteofactors, Institute of Endocrinology , Prague, Czech Republic. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Endocrine Disruptors, Steroids, Prostate. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate cancer (PCa) is a hormone-dependent malignancy governed by steroid signaling. Despite characterization of androgen pathways, the broader intraprostatic steroid environment remains underexplored. Endocrine-disrupting chemicals (EDCs) may modulate these processes, yet their tissue distribution is largely unknown. We aimed to comprehensively profile intraprostatic steroids and EDCs and assess their associations with tumor aggressiveness, prognosis, and risk stratification. Thirty steroids and 16 EDCs were quantified using liquid chromatography–tandem mass spectrometry in cancerous tissue, non-cancerous tissues (from peripheral and transition zones), and plasma from 173 patients with localized PCa undergoing robot-assisted radical prostatectomy. Analysis of variance was used to compare analyte levels across biological matrices and according to disease aggressiveness, multivariate statistical models evaluated associations with patient prognosis and risk categories, and machine learning (ML) models were applied for risk stratification. Steroid profiles differed markedly between plasma and prostate tissue, whereas EDCs accumulated in the prostate and were generally not associated with plasma concentrations. Cancerous tissue showed lower conjugated dehydroepiandrosterone (DHEA) and higher pregnenolone, corticoids, and testosterone compared to non-cancerous tissue. Elevated intratumoral cortisol, cortisone, androstenedione, conjugated testosterone, 7-ketoDHEA, and estrone were associated with greater tumor aggressiveness. Higher intratumoral parabens correlated with increased postoperative PSA, while conjugated dihydrotestosterone (DHT) and phytoestrogen daidzein were inversely associated with PSA levels. Higher EDC burden and intratumoral steroid levels were associated with higher risk categories. In contrast, DHT showed a consistent protective profile, being negatively associated with both prognosis and risk classification. Integrating steroids and EDCs improved ML-based risk classification beyond preoperative clinical variables.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsEndocrine DisruptorsSteroidsProstateMaleHumansAgedMiddle AgedPrognosis

Stichwörter der Autor:innen

LC-MS/MSendocrine disruptorendocrine-disrupting chemicalprostate cancersteroid hormone

Substanzen

Endocrine DisruptorsSteroids

Autor:innen und Institutionen

  • Department of Steroids and Proteofactors, Institute of Endocrinology , Prague, Czech Republic.
  • Department of Urology, First Faculty of Medicine, Charles University , Prague, Czech Republic.
  • Department of Urology, Military University Hospital , Prague, Czech Republic.
  • Department of Pathology, Military University Hospital , Prague, Czech Republic.

ORCID-Profile: Jana Vitku

Zitieren

APA

Vitku, J., Skodova, T., Varausova, A., Gadus, L., Horenitzky, M., Novakova, M., Hill, M., Svojtkova, M., Kolatorova, L., Lukaskova, A., & Heracek, J. (2026). Intraprostatic steroid hormones and endocrine disruptors in prostate cancer. Endocrine-Related Cancer, 33(7). https://doi.org/10.1530/erc-26-0153

Vancouver

Vitku J, Skodova T, Varausova A, Gadus L, Horenitzky M, Novakova M, et al. Intraprostatic steroid hormones and endocrine disruptors in prostate cancer. Endocrine-Related Cancer. 2026;33(7). doi:10.1530/erc-26-0153

BibTeX
@article{Vitku2026,
  author = {Vitku, Jana and Skodova, Tereza and Varausova, Anezka and Gadus, Lukas and Horenitzky, Michal and Novakova, Marie and Hill, Martin and Svojtkova, Michaela and Kolatorova, Lucie and Lukaskova, Adela and Heracek, Jiri},
  title = {Intraprostatic steroid hormones and endocrine disruptors in prostate cancer},
  journal = {Endocrine-Related Cancer},
  year = {2026},
  volume = {33},
  number = {7},
  doi = {10.1530/erc-26-0153}
}
Kostenlos starten →